BERG – Back to Biology for a Healthier Tomorrow
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.
BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials.
Our mission is to improve the lives of patients. BERG aims to be the leader in precision medicine to solve the healthcare challenges that face our society. We believe that our drug candidates and diagnostics will result in faster clinical validation and safer, more effective therapies for patients worldwide. At BERG we are precision medicine, and at the center of our innovative platform is the patient.